(Press-News.org) The University of Maryland School of Medicine (UMSOM) Palliative Medicine Program has launched a new clinical trial funded by the National Institute on Aging to explore a potential treatment for agitation in patients with dementia nearing the end of life. The study focuses on an investigational oral drug, T2:C100, which contains the two active ingredients in cannabis: THC and CBD.
Currently, standard medications such as morphine, valium, and Haldol are commonly used to manage agitation in hospice-eligible patients with dementia. However, these treatments are often ineffective or associated with burdensome side effects, including respiratory suppression, excessive sedation, and worsening confusion. This trial seeks to determine whether T2:C100 can more effectively reduce agitation than a placebo, potentially minimizing reliance on these medications while enhancing patient comfort and quality of care.
“This study is important because there are no FDA-approved medications to manage agitation at the end of life in dementia,” said Raya Kheirbek, MD, Principal Investigator and Division Chief of Geriatrics and Palliative Medicine at UMSOM and UMMC “More than half of people with dementia will receive hospice care, and 70% of them are given psychotropic medications to manage agitation — often with limited benefit and problematic side effects.”
Researchers seek to recruit a total of 120 participants who will be randomly assigned to take either T2:C100 or a placebo twice a day for 12 weeks. In order to ensure objective results, the study is double-blind: neither participants nor clinicians will know which treatment is being administered. After 12 weeks, all participants will be given the option to continue participation for an additional 12 weeks on T2:C100.
UMSOM is one of 13 national trial sites involved in this study, which is listed on ClinicalTrials.gov. The trial will be conducted in the General Clinical Research Center at UMSOM.
“We’re testing a potential treatment for a condition that’s not only common but incredibly distressing,” said Dr. Jacobo Mintzer, Principal Investigator, professor at the Medical University of South Carolina (MUSC) and staff physician at the Ralph H. Johnson VA Health Care System. “Our hope is that clinicians and caregivers will consider enrolling eligible patients. Success in this trial could open the door to larger studies and wider treatment availability.”
The clinical trial is part of the NIH-sponsored Alzheimer’s Clinical Trials Consortium (ACTC) and titled the Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY) Study.
Enrollment Contact Information
Families interested in participating or learning more about the study can call or email:
The University of Maryland School of Medicine
Gerontology, Geriatrics & Palliative Medicine Division
(410)328-7849
LiBBY@som.umaryland.edu
Or visit www.LIBBYStudy.org to view more study locations.
The Alzheimer’s Clinical Trial Consortium (ACTC) is led by Paul Aisen, MD, Alzheimer’s Therapeutic Research Institute at the University of Southern California (USC), Ron Petersen, MD, of Mayo Clinic, and Reisa Sperling, MD of the Brigham and Women’s Hospital and Harvard. Jacobo Mintzer, MD, MBA, of the Medical College of South Carolina in Charleston and Brigid Reynolds of Georgetown University were awarded this grant from the National Institutes of Health, National Institute of Aging. The investigators report no conflicts of interest.
Alzheimer’s Clinical Trials Consortium (ACTC) is funded by a Cooperative Agreement from the National Institute on Aging and the National Institutes of Health. Cooperative Agreement number U24AG057437.
Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY)
Principal Investigators: Jacobo Mintzer, MD, MBA, and Brigid Reynolds, MSN, ANP-BC
NIA/NIH Grant #: R01 AG068324-01
END
University of Maryland School of Medicine launches groundbreaking study on THC/CBD therapy for dementia-related agitation at end of life
First-of-its-kind clinical trial investigates cannabis-based treatment to improve quality of care for hospice eligible patients with dementia
2025-07-09
ELSE PRESS RELEASES FROM THIS DATE:
Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.006
This new article publication from Acta Pharmaceutica Sinica B, discusses targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery.
Triple-negative breast cancer (TNBC) is aggressive, with high recurrence rates and poor prognosis. Paclitaxel (PTX) remains a key chemotherapeutic agent for TNBC, but its efficacy diminishes due to the emergence of drug resistance, largely driven by cancer stem-like cells (CSCs), vasculogenic mimicry (VM) formation and tumor immunosuppressive ...
SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.017
This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.
Idiopathic pulmonary fibrosis (IPF), a chronic interstitial lung disease, is characterized by aberrant wound healing, excessive scarring and the formation of myofibroblastic foci. Although the role of alternative splicing (AS) in the pathogenesis of organ fibrosis has garnered increasing attention, ...
Psychological stress-activated NR3C1/NUPR1 axis promotes ovarian tumor metastasis
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.001
This new article publication from Acta Pharmaceutica Sinica B, discusses how a psychological stress-activated NR3C1/NUPR1 axis promotes ovarian tumor metastasis.
Ovarian tumor (OT) is the most lethal form of gynecologic malignancy, with minimal improvements in patient outcomes over the past several decades. Metastasis is the leading cause of ovarian cancer-related deaths, yet the underlying mechanisms remain poorly understood.
Psychological stress is known to activate ...
An anti-complement homogeneous polysaccharide from Houttuynia cordata ameliorates acute pneumonia with H1N1 and MRSA coinfection through rectifying Treg/Th17 imbalance in the gut–lung axis and NLRP3 i
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.008
This new article publication from Acta Pharmaceutica Sinica B, discusses how an anti-complement homogeneous polysaccharide from Houttuynia cordata ameliorates acute pneumonia with H1N1 and MRSA coinfection through rectifying Treg/Th17 imbalance in the gut–lung axis and NLRP3 inflammasome activation.
The coinfection of respiratory viruses and bacteria is a major cause of morbidity and mortality worldwide, despite the development of vaccines and powerful antibiotics. As a macromolecule that is difficult to absorb in the gastrointestinal tract, a homogeneous polysaccharide from Houttuynia cordata (HCPM) has been reported ...
ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.018
This new article publication from Acta Pharmaceutica Sinica B, discusses how ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells.
Chemotherapy is currently the mainstay of systemic management for triple-negative breast cancer (TNBC), but chemoresistance significantly impacts patient outcomes.
This research indicates that Doxorubicin (Dox)-resistant TNBC cells exhibit increased glycolysis and ATP generation compared to their parental cells, with this metabolic shift contributing to chemoresistance. It was discovered ...
A photodynamic nanohybrid system reverses hypoxia and augment anti-primary and metastatic tumor efficacy of immunotherapy
2025-07-09
https://doi.org/10.1016/j.apsb.2025.04.007
This new article publication from Acta Pharmaceutica Sinica B, discusses how a photodynamic nanohybrid system reverses hypoxia and augments anti-primary and metastatic tumor efficacy of immunotherapy.
Photodynamic immunotherapy is a promising strategy for cancer treatment. However, the dysfunctional tumor vasculature results in tumor hypoxia and the low efficiency of drug delivery, which in turn restricts the anticancer effect of photodynamic immunotherapy.
The ...
Acta Pharmaceutica Sinica B Volume 15, Issue 6 Publishes
2025-07-09
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/15/issue/6
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
APSB is a monthly journal, in English, which publishes ...
From injury to agony: Scientists discover brain pathway that turns pain into suffering
2025-07-09
LA JOLLA (July 9, 2025)—Pain isn’t just a physical sensation—it also carries emotional weight. That distress, anguish, and anxiety can turn a fleeting injury into long-term suffering.
Researchers at the Salk Institute have now identified a brain circuit that gives physical pain its emotional tone, revealing a new potential target for treating chronic and affective pain conditions such as fibromyalgia, migraine, and post-traumatic stress disorder (PTSD).
Published on July 9, 2025, in Proceedings of the National Academy of Sciences, the study identifies a group of neurons in a central brain area called the thalamus ...
Molecular simulations show graphite ‘hijacks’ diamond formation through unexpected crystallization pathways
2025-07-09
The graphite found in your favorite pencil could have instead been the diamond your mother always wears. What made the difference? Researchers are finding out.
How molten carbon crystallizes into either graphite or diamond is relevant to planetary science, materials manufacturing and nuclear fusion research. However, this moment of crystallization is difficult to study experimentally because it happens very rapidly and under extreme conditions.
In a new study published July 9 in Nature Communications, researchers from the University of California, Davis and George Washington ...
Scientific breakthrough uses cold atoms to unlock cosmic mysteries
2025-07-09
Scientists have used ultracold atoms to successfully demonstrate a groundbreaking method of particle acceleration that could unlock new understanding of how cosmic rays behave, a new study reveals.
After more than 70 years from its formulation, researchers have observed the Fermi acceleration mechanism in a laboratory by colliding ultracold atoms against engineered movable potential barriers – delivering a significant milestone in high-energy astrophysics and beyond.
Fermi acceleration is the mechanism responsible for the generation of cosmic rays, as postulated by physicist Enrico Fermi in 1949. ...
LAST 30 PRESS RELEASES:
Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk
Promising new drug for people with stubborn high blood pressure
One shot of RSV vaccine effective against hospitalization in older adults for two seasons
Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults
Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis
Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine
High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults
Prevalence, determinants, and time trends of cardiovascular health in the WHO African region
New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers
CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients
Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock
Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes
High Mountain Asia’s shrinking glaciers linked to monsoon changes
All DRII-ed up: How do plants recover after drought?
Research on stigma says to just ‘shake it off’
Scientists track lightning “pollution” in real time using NASA satellite
Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy
Hot days make for icy weather, Philippine study finds
Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology
World's first clinical trial showing lubiprostone aids kidney function
Capturing language change through the genes
Public trust in elections increases with clear facts
Thawing permafrost raised carbon dioxide levels after the last ice age
New DNA test reveals plants’ hidden climate role
Retinitis pigmentosa mouse models reflect pathobiology of human RP59
Cell’s ‘antenna’ could be key to curing diseases
Tiny ocean partnership between algae and bacteria reveals secrets of evolution
Scientists uncover cellular “toolkit” to reprogram immune cells for cancer therapy
Blocking protein control pathway slows rhabdomyosarcoma growth in mice
2026 Hertz Fellowship Application Now Open
[Press-News.org] University of Maryland School of Medicine launches groundbreaking study on THC/CBD therapy for dementia-related agitation at end of lifeFirst-of-its-kind clinical trial investigates cannabis-based treatment to improve quality of care for hospice eligible patients with dementia